CN106619662B - 一种含有富马酸替诺福韦二吡呋酯的口服干混悬剂及其制备方法 - Google Patents
一种含有富马酸替诺福韦二吡呋酯的口服干混悬剂及其制备方法 Download PDFInfo
- Publication number
- CN106619662B CN106619662B CN201611268720.1A CN201611268720A CN106619662B CN 106619662 B CN106619662 B CN 106619662B CN 201611268720 A CN201611268720 A CN 201611268720A CN 106619662 B CN106619662 B CN 106619662B
- Authority
- CN
- China
- Prior art keywords
- tenofovir disoproxil
- disoproxil fumarate
- parts
- dry suspension
- suspension containing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
Abstract
Description
样品编号 | 沉降体积比 |
实施例2 | 0.96 |
实施例3 | 0.97 |
实施例4 | 0.96 |
实施例5 | 0.96 |
实施例6 | 0.98 |
实施例7 | 0.95 |
实施例8 | 0.97 |
实施例9 | 0.95 |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611268720.1A CN106619662B (zh) | 2016-12-31 | 2016-12-31 | 一种含有富马酸替诺福韦二吡呋酯的口服干混悬剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611268720.1A CN106619662B (zh) | 2016-12-31 | 2016-12-31 | 一种含有富马酸替诺福韦二吡呋酯的口服干混悬剂及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106619662A CN106619662A (zh) | 2017-05-10 |
CN106619662B true CN106619662B (zh) | 2020-06-16 |
Family
ID=58838078
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201611268720.1A Active CN106619662B (zh) | 2016-12-31 | 2016-12-31 | 一种含有富马酸替诺福韦二吡呋酯的口服干混悬剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106619662B (zh) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110577555A (zh) * | 2018-06-08 | 2019-12-17 | 欣凯医药化工中间体(上海)有限公司 | 一种无定形的替诺福韦十八烷氧乙酯的制备方法及其应用 |
CN110917197A (zh) * | 2019-12-31 | 2020-03-27 | 常州恒邦药业有限公司 | 一种替诺福韦酯与恩曲他滨的药物组合物及其制备方法 |
CN111773230A (zh) * | 2020-08-17 | 2020-10-16 | 深圳市道科思医药有限公司 | 热熔挤出的替诺福韦酯药物组合物 |
CN113599366B (zh) * | 2021-08-12 | 2022-11-11 | 南京海纳医药科技股份有限公司 | 一种富马酸替诺福韦二吡呋酯颗粒及其制备方法 |
CN114948970A (zh) * | 2022-06-07 | 2022-08-30 | 安徽贝克生物制药有限公司 | 含依非韦伦的药物组合物及其制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20150117497A (ko) * | 2014-04-10 | 2015-10-20 | 성광제약주식회사 | 테노포비르디소프록실푸마레이트 필름형 제제 및 그 제조방법 |
WO2016044182A1 (en) * | 2014-09-16 | 2016-03-24 | Gilead Sciences, Inc. | Solid forms of a toll-like receptor modulator |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1502334A (zh) * | 2002-11-20 | 2004-06-09 | 中国人民解放军军事医学科学院放射医 | 含阿德福韦地匹福酯的药物组合物 |
CN102920673A (zh) * | 2012-11-23 | 2013-02-13 | 南京森博医药研发有限公司 | 一种无定形阿德福韦酯固体分散口服剂型及其制备方法 |
CN103330683B (zh) * | 2013-06-26 | 2014-12-03 | 神威药业集团有限公司 | 一种富马酸替诺福韦酯细粒剂 |
CN105147628A (zh) * | 2015-08-24 | 2015-12-16 | 苏州弘森药业有限公司 | 一种富马酸替诺福韦二吡呋酯微丸片及其制备方法 |
-
2016
- 2016-12-31 CN CN201611268720.1A patent/CN106619662B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20150117497A (ko) * | 2014-04-10 | 2015-10-20 | 성광제약주식회사 | 테노포비르디소프록실푸마레이트 필름형 제제 및 그 제조방법 |
WO2016044182A1 (en) * | 2014-09-16 | 2016-03-24 | Gilead Sciences, Inc. | Solid forms of a toll-like receptor modulator |
Non-Patent Citations (1)
Title |
---|
Thermal Stability of Tenofovir Disoproxil Fumarate in Suspension;Hiroki Yagura,et al.;《Jpn J Pharm Health Care Sci》;20141231;230-236 * |
Also Published As
Publication number | Publication date |
---|---|
CN106619662A (zh) | 2017-05-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106619662B (zh) | 一种含有富马酸替诺福韦二吡呋酯的口服干混悬剂及其制备方法 | |
EP1523974B1 (en) | Composition for rapid disintegrating tablet in oral cavity | |
EP1674083B1 (en) | Tablet quickly disintegrating in oral cavity | |
JP5053865B2 (ja) | 口腔内崩壊性固形製剤の製造法 | |
AU676315B2 (en) | Stabilized solid pharmaceutical preparation and method of producing the same | |
WO1993015724A1 (en) | Fast soluble tablet | |
CN108272765B (zh) | 含盐酸伐地那非的药物组合物、口崩片及其制备、应用 | |
US8349361B2 (en) | Composition for rapid disintegrating tablet in oral cavity | |
KR101562608B1 (ko) | 호흡기 질환에 작용하는 복합 화학 약물, 그들의 제조 방법 및 용도 | |
JP2004315483A (ja) | 口腔内崩壊錠剤 | |
Ratnaparkhi | Formulation and development of taste masked orally disintegrating tablets of perindopril erbumine by direct compression method | |
JP6308938B2 (ja) | 粒状物を製造する方法 | |
JP2003055199A (ja) | 徐放性マイクロペレット | |
JP6775155B2 (ja) | 錠剤 | |
TW201517933A (zh) | 超高速崩解錠劑及其製造方法 | |
CN109157527B (zh) | 一种厄贝沙坦胶囊及其制备方法 | |
CN115124420B (zh) | 大黄酸与苦参碱共晶物水合物及制备方法和其组合物与用途 | |
EP3238712B1 (en) | Very rapidly disintegrating tablet, and method for producing same | |
JPH0797325A (ja) | 安定な固形製剤およびその製造法 | |
CN105407875A (zh) | 包含异烟肼颗粒和利福喷汀颗粒的呈包衣片剂形式的抗结核病的稳定的药物组合物及其制备方法 | |
CN115702898B (zh) | 一种btk抑制剂固体制剂及其制备方法 | |
JPS589082B2 (ja) | 小粒剤の製造法 | |
CN117442573A (zh) | 一种右佐匹克隆药物组合物 | |
CN101647771B (zh) | 一种水飞蓟宾琥珀酸酯二钠盐口服制剂及其制备方法 | |
TW202220643A (zh) | 含有米羅巴林苯磺酸鹽之口腔內崩散錠 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Shi Lei Inventor after: You Jinzong Inventor after: Jiang Shanhui Inventor after: Pan Shihao Inventor before: Jiang Shanhui Inventor before: You Jinzong Inventor before: Shi Lei Inventor before: Pan Shihao |
|
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20200515 Address after: No.168, Shanghai Road, Binjiang fine chemical park, Qidong, Nantong, Jiangsu Applicant after: JIANGSU COBEN PHARMACEUTICAL Co.,Ltd. Applicant after: HANGZHOU KANGBEN PHARMACEUTICAL TECHNOLOGY Co.,Ltd. Applicant after: HANGZHOU COBEN PHARMACEUTICAL R&D Co.,Ltd. Address before: Hangzhou City, Zhejiang province 311121 Yuhang District No. 1378 West Street warehouse before building 1 building F Room 601 Applicant before: HANGZHOU KANGBEN PHARMACEUTICAL TECHNOLOGY Co.,Ltd. Applicant before: HANGZHOU COBEN PHARMACEUTICAL R&D Co.,Ltd. Applicant before: JIANGSU COBEN PHARMACEUTICAL Co.,Ltd. Applicant before: HANGZHOU COBEN PHARMACEUTICAL Co.,Ltd. |
|
GR01 | Patent grant | ||
GR01 | Patent grant |